TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region of the nasal cavity, and have desirable particle size distribution, spray pattern and plume geometry A shelf-stable dry powder vaccine formulation delivered intranasally could dramatically change the existing vaccine landscape

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here